MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company that provides next-level therapies to elevate care.
Total raised: $730M
Investors 1
| Date | Name | Website |
| 04.07.2025 | Hercules C... | htgc.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 16.07.2026 | - | $230M | - |
| 03.04.2025 | - | $500M | - |
Mentions in press and media 18
| Date | Title | Description |
| 18.08.2026 | Three Swiss biotechs report progress across their clinical programmes | MoonLake Immunotherapeutics, a Zug-based clinical-stage biotech founded in 2021, reported topline results from IZAR-1, a Phase 3 trial of its lead candidate sonelokimab in adults with active psoriatic arthritis who have not previously rece... |
| 16.07.2026 | Moonlake Therapeutics raises USD 230 million in public offering | End of June MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on therapies for inflammatory skin and joint diseases, announced the pricing of an underwritten public offering of 9,000,000 Class A ordinary shares at... |
| 04.02.2026 | Two publications and an FDA fast track designation for Swiss biotechs | MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company focused on developing advanced therapies for inflammatory diseases, announced that its lead asset, sonelokimab, has been granted Fast Track designation by the U.S. Foo... |
| 07.11.2025 | Development milestones and financing for biotech companies | Timeline, a longevity biotech company behind Mitopure® (Urolithin A) — a postbiotic that stimulates mitophagy, the body’s cellular recycling process critical for mitochondrial and metabolic health — has published a new clinical study on im... |
| 03.04.2025 | MoonLake Immunotherapeutics secures up to $500 Million in non-dilutive financing | MoonLake has entered into an agreement with Hercules Capital, Inc., a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital. $75 million will b... |
| 11.06.2024 | Biotech startups make clinical progress | The U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application from Anaveon to conduct a Phase I/II study evaluating the safety and clinical activity of their drug candidate ANV600. As the company’s... |
| 27.05.2024 | Biotechs record clinical trial successes | Noema Pharma, a clinical-stage biotech targeting debilitating neuroscience disorders, has treated the first patient in an open-label Phase 2a study (NOE-PPM-201) evaluating the safety and efficacy of NOE-115, a broad-spectrum monoamine mod... |
| 01.05.2024 | Triumphs and a setback in the biotech sector | The successful advancement of CDR-Life Inc.’s Phase 1 study with BI 771716, its therapeutic candidate in partnership with Boehringer Ingelheim (BI) for the treatment of geographic atrophy (GA), has triggered a milestone payment to the star... |
| 06.11.2023 | XBI biotech index rises, giving investors a shred of hope | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Happy Monday. So, we’ve got a welcome bump in the XBI, see that European regulatory conditions are prompting Ozempic... |
| 11.05.2023 | SHL Medical and MoonLake Immunotherapeutics collaborate to develop sonelokimab autoinjector | ZUG, Switerland, May 11, 2023 /PRNewswire/ -- SHL Medical, a world-leading provider of advanced drug delivery solutions, announced that it has signed a collaboration agreement with MoonLake Immunotherapeutics, a clinical-stage biotechnology... |
Show more